Regeneron Pharmaceuticals Aktie 965755 / US75886F1075
744.41
USD
-17.83
USD
-2.34%
19.11.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Regeneron Pharmaceuticals Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2022 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2021 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2020 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2019 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2018 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2017 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2016 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2015 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2014 | Regeneron Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
Gewinn je Aktie- Regeneron Pharmaceuticals
| 10.3 17 | 21.3 18 | 18.5 19 | 30.5 20 | 72.0 21 | 38.2 22 | 34.8 23 |
Umsatz je Aktie- Regeneron Pharmaceuticals
| 50.6 17 | 58.5 18 | 68.6 19 | 73.8 20 | 143 21 | 107 22 | 115 23 |
KGV- Regeneron Pharmaceuticals
| 36.4 17 | 17.5 18 | 20.3 19 | 15.8 20 | 8.8 21 | 18.9 22 | 25.3 23 |
Regeneron Pharmaceuticals Inc.: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 |
| Gewinn je Aktie unverwässert | 11.27 | 22.65 | 19.38 | 32.65 | 76.40 | 40.51 | 37.05 |
| Gewinn je Aktie verwässert | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 |
| Dividende pro Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Regeneron Pharmaceuticals Inc.: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 50.64 | 58.46 | 68.62 | 73.82 | 143.24 | 107.25 | 115.37 |
| KGV (Jahresendkurs, EPS unverwässert) | 36.36 | 17.54 | 20.34 | 15.83 | 8.77 | 18.88 | 25.26 |
| KGV (Jahresendkurs, EPS verwässert) | 36.36 | 17.54 | 20.34 | 15.83 | 8.77 | 18.88 | 25.26 |
| KGV (Jahresendkurs) | 36.36 | 17.54 | 20.34 | 15.83 | 8.77 | 18.88 | 25.26 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 69.72 | 74.63 | 74.90 | 64.24 | 73.79 | 77.42 | 78.40 |
| Fremdkapitalquote in % | 30.28 | 25.37 | 25.10 | 35.76 | 26.21 | 22.58 | 21.60 |
Regeneron Pharmaceuticals Inc.: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 5’872.23 | 6’710.80 | 7’863.40 | 8’497.10 | 16’071.70 | 12’172.90 | 13’117.20 |
| Umsatzveränderung in % | 20.82 | 14.28 | 17.18 | 8.06 | 89.14 | -24.26 | 7.76 |
| Bruttoergebnis vom Umsatz | 5’329.70 | 6’128.50 | 6’870.90 | 7’141.30 | 13’348.00 | 10’467.70 | 10’872.70 |
| Bruttoergebnisveränderung in % | 19.61 | 14.99 | 12.11 | 3.94 | 86.91 | -21.58 | 3.87 |
| Operatives Ergebnis | 2’079.59 | 2’534.40 | 2’209.80 | 3’576.60 | 8’946.80 | 5’385.60 | 4’348.60 |
| Veränderung Operatives Ergebnis in % | 56.27 | 21.87 | -12.81 | 61.85 | 150.15 | -39.80 | -19.26 |
| Ergebnis vor Steuern | 2’078.51 | 2’553.50 | 2’429.10 | 3’810.40 | 9’325.80 | 4’858.80 | 4’199.30 |
| Veränderung Ergebnis vor Steuern in % | 56.30 | 22.85 | -4.87 | 56.86 | 144.75 | -47.90 | -13.57 |
| Ergebnis nach Steuer | 1’198.51 | 2’444.40 | 2’115.80 | 3’513.20 | 8’075.30 | 4’338.40 | 3’953.60 |
| Veränderung Ergebnis nach Steuer in % | 33.83 | 103.95 | -13.44 | 66.05 | 129.86 | -46.28 | -8.87 |
Regeneron Pharmaceuticals Inc.: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 2’668 | 2’977 | 3’716 | 6’138 | 6’666 | 6’609 | 7’158 |
| Langzeit Gesamtverbindlichk. pro Aktie | 14.24 | 14.08 | 14.68 | 32.17 | 25.15 | 31.64 | 34.13 |
| Eigenkapital | 6’144 | 8’757 | 11’090 | 11’025 | 18’769 | 22’664 | 25’973 |
| Veränderung Eigenkapital in % | 38.09 | 42.53 | 26.63 | -0.58 | 70.23 | 20.75 | 14.60 |
| Bilanzsumme | 8’812 | 11’735 | 14’805 | 17’163 | 25’435 | 29’273 | 33’131 |
| Veränderung Bilanzsumme in % | 26.20 | 33.17 | 26.17 | 15.93 | 48.19 | 15.09 | 13.18 |
Regeneron Pharmaceuticals Inc.: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 11.27 | 22.65 | 19.38 | 32.65 | 76.40 | 40.51 | 37.05 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 31.81 | 100.98 | -14.46 | 68.51 | 133.99 | -46.98 | -8.53 |
| Gewinn je Aktie (verwässert) | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 |
| Veränderung Gewinn je Aktie (verwässert) in % | 34.29 | 105.90 | -13.28 | 65.32 | 135.80 | -46.89 | -9.03 |
| Anzahl Mitarbeiter | 6’200 | 7’400 | 8’100 | 9’123 | 10’368 | 11’851 | 13’450 |
| Veränderung Anzahl Mitarbeiter in % | 14.81 | 19.35 | 9.46 | 12.63 | 13.65 | 14.30 | 13.49 |
Regeneron Pharmaceuticals Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | Quartalszahlen | 31.01.2025 |
| Regeneron Pharmaceuticals Inc. | Quartalszahlen | 01.05.2025 |
| Regeneron Pharmaceuticals Inc. | Quartalszahlen | 31.07.2025 |
| Regeneron Pharmaceuticals Inc. | Quartalszahlen | 30.10.2025 |
Regeneron Pharmaceuticals Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 31.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 01.08.2024 |
| Hauptversammlung | Annual General Meeting | 14.06.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 02.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 02.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 02.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 03.08.2023 |
| Hauptversammlung | Annual General Meeting | 09.06.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 04.05.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 03.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 03.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 03.08.2022 |
| Hauptversammlung | Annual General Meeting | 10.06.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 04.05.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 04.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98.03 |
| Vanguard Group, Inc. (Subfiler) | 8.16 |
| The Vanguard Group, Inc. | 8.15 |
| Fidelity Management & Research Co. LLC | 7.37 |
| JPMorgan Investment Management, Inc. | 5.25 |
| Capital Research & Management Co. (World Investors) | 4.79 |
| State Street Corp. | 4.52 |
| Capital Research & Management Co. (World Investors) | 3.96 |
| Vanguard Total Stock Market ETF | 3.17 |
| Capital Research & Management Co. (International Investors) | 3.09 |
| BlackRock Fund Advisors | 2.92 |
| American Funds Growth Fund of America | 2.89 |
| Vanguard 500 Index Fund | 2.56 |
| Fidelity Contrafund | 2.46 |
| BlackRock Institutional Trust Co. NA | 2.16 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 8’100 | 9’123 | 10’368 | 11’851 | 13’450 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.97 | 0.93 | 1.55 | 1.03 | 0.98 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 7’689 | 9’779 | 14’015 | 15’884 | 19’479 |
| Summe Anlagevermögen | 7’116 | 7’384 | 11’420 | 13’389 | 13’651 |
| Summe Aktiva | 14’805 | 17’163 | 25’435 | 29’273 | 33’131 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 714 | 2’696 | 2’700 | 2’701 | 2’703 |
| Summe Fremdkapital | 3’716 | 6’138 | 6’666 | 6’609 | 7’158 |
| Summe Eigenkapital | 11’090 | 11’025 | 18’769 | 22’664 | 25’973 |
| Summe Passiva | 14’805 | 17’163 | 25’435 | 29’273 | 33’131 |
Adresse
| 777 Old Saw Mill River Road, 10591-6707 Tarrytown | |
| Telefon | +1 (914) 847-7000 |
| URL | http://www.regeneron.com |
Management
|
Alan Shuldiner
Vice President-Translational Genetics |
|
Andrew J. Murphy
Executive Vice President-Research |
|
Arthur Frederick Ryan
Independent Director |
|
Benjamin Drosman
SVP-Regulatory Compliance & Global Development |
|
Boaz Hirshberg
SVP-Clinical Sciences General Medicine |
|
Bob McCowan
Chief Information Officer & Senior VP-IT |
|
Bola Akinlade
Senior Vice President-Clinical Development |
|
Bonnie L. Bassler
Independent Director |
|
Christine A. Poon
Lead Independent Director |
|
Christine Childrose
Senior Vice President-Human Resources & Operations |
|
Christopher Robert Fenimore
Chief Financial Officer & Senior VP-Finance |
|
Christos Kyratsous
Senior Vice President-Research |
|
Craig B. Thompson
Independent Director |
|
Daniel P. van Plew
EVP, GM-Industrial Operations & Product Supply |
|
David Paul Schenkein
Director |
|
David Simon
Senior Vice President-Business Operations |
|
George Damis Yancopoulos
Co-Chairman & Co-President |
|
George L. Sing
Independent Director |
|
Gerald Underwood
Senior Vice President-Technical Operations |
|
Huda Y. Zoghbi
Independent Director |
|
Jason Pitofsky
Vice President & Controller |
|
John Calabro
Senior Vice President-Internal Auditor |
|
Johnathan M. Lancaster
Senior Vice President-Global Medical Affairs |
|
Joseph J. LaRosa
Secretary, Executive VP & General Counsel |
|
Joseph L. Goldstein
Independent Director |
|
Kathryn W. Guarini
Independent Director |
|
Kerry K. Reinertsen
Senior Vice President-Strategic Alliances |
|
Leonard Brooks
Treasurer & Senior Vice President |
|
Leonard S. Schleifer
Co-Chairman, Co-President & CEO |
|
Lori Morton
Senior Vice President-Research |
|
Lynn Macdonald
Senior Vice President-Research |
|
Marion McCourt
Executive Vice President-Commercial |
|
Mark Hudson
Head-Investor Relations |
|
Mark Volpe
Senior Vice President-Tax |
|
Maya Bermingham
Senior VP-Public Policy & Government Affairs |
|
Melissa Lozner
Chief Compliance Officer & Senior Vice President |
|
Michael S. Brown
Independent Director |
|
N. Anthony Coles
Independent Director |
|
Ned Braunstein
SVP-Regulatory Affairs & Global Patient Safety |
|
Neil Stahl
Executive VP-Research & Development |
|
Nouhad Husseini
Senior VP-Business Development |
|
Patrice Gilooly
Senior VP-Quality Assurance & Operations |
|
Ryan Crowe
Head-Investor Relations |
|
Sally A. Paull
Executive Vice President-Human Resources |
|
Smita Pillai
Chief Diversity, Equity & Inclusion Officer |